Heidelberg Pharma sets 175 µg/kg RP2D for pamlectabart tismanitin in Phase I/IIa multiple myeloma trial
Heidelberg Pharma presented new Phase I/IIa data on pamlectabart tismanitin at the IMS Annual Meeting 2026. The trial supported a Phase 2 dose selection, with safety remaining favorable and no dose-limiting ceiling identified. Responses were reported in heavily pretreated relapsed or refractory multiple myeloma patient